Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Deniz Can Güven, Taha Koray Şahin, Enes Erul, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 132

Showing 1-25 of 132 citing articles:

Calculus bovis inhibits M2 tumor-associated macrophage polarization via Wnt/β-catenin pathway modulation to suppress liver cancer
Zhen Huang, Fanying Meng, Lin-Zhu Lu, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 29, pp. 3511-3533
Open Access | Times Cited: 22
Polymeric nanoparticles as delivery vehicles for targeted delivery of chemotherapy drug fludarabine to treat hematological cancers
Mehrab Pourmadadi, Hamed Mirzaei Dehaghi, Amirhossein Ghaemi, et al.
Inorganic Chemistry Communications (2024) Vol. 167, pp. 112819-112819
Closed Access | Times Cited: 11
Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy
Lingzhi Wang, Shengnan Bi, Zhuo Li, et al.
Biomaterials (2024) Vol. 313, pp. 122766-122766
Closed Access | Times Cited: 8
The association between HALP score and survival in patients treated with immune checkpoint inhibitors
Taha Koray Şahin, Deniz Can Güven, Mine Durukan, et al.
Expert Review of Anticancer Therapy (2025), pp. 1-9
Closed Access | Times Cited: 1
Preclinical study of inetetamab combined with atezolizumab to synergistically inhibit HER2 and PD-L1 in the treatment of ovarian cancer
Feiquan Ying, Xuyang Zhou, Mengqing Chen, et al.
Deleted Journal (2025) Vol. 33, Iss. 1, pp. 200938-200938
Open Access | Times Cited: 1
Efficacy and safety of different drugs in patients with HER2-positive gastric cancer: network meta-analysis
Jie Zhang, Chunluan Yuan, Xiao Ma
Systematic Reviews (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy
Taha Koray Şahin, Yakup Özbay, Ahmet Yasir Altunbulak, et al.
International Journal of Clinical Oncology (2024) Vol. 29, Iss. 6, pp. 822-831
Closed Access | Times Cited: 7
The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapy
Sajjad Ahmadpour, Mohammad Amin Habibi, Farzaneh Sadat Ghazi, et al.
Cancer Treatment and Research Communications (2024) Vol. 40, pp. 100823-100823
Open Access | Times Cited: 6
Myeloid cell differentiation-related gene signature for predicting clinical outcome, immune microenvironment, and treatment response in lung adenocarcinoma
Di Wu, Yibing Liu, Jianjun Liu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Explainable machine learning models for early gastric cancer diagnosis
Hongyang Du, Qingfen Yang, Aimin Ge, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Bioinformatics analysis to disclose shared molecular mechanisms between type-2 diabetes and clear-cell renal-cell carcinoma, and therapeutic indications
Reaz Ahmmed, Md. Bayazid Hossen, Alvira Ajadee, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Role of mast cell in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
Masaaki Nishi, Shoko Yamashita, Chie Takasu, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Blood metabolites reflect the effect of gut microbiota on differentiated thyroid cancer: a Mendelian randomization analysis
Hanfei Zhang, Yuhao Li, Lin Li
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Prognostic Value of the C-PLAN Index in Metastatic Renal Cell Carcinoma Treated with Nivolumab
Gökhan Şahin, Caner Acar, Haydar Çağatay Yüksel, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 7, pp. 2217-2217
Open Access
Machine learning-based screening and validation of liver metastasis-specific genes in colorectal cancer
Shiyao Zheng, Hongxin He, Jianfeng Zheng, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Personalized neoantigen cancer vaccines: current progression, challenges and a bright future
Dawei Wu, Shuopeng Jia, Shujun Xing, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Tadahiro Kuribayashi, Rie Kinoshita, Kiichiro Ninomiya, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Whole transcriptome analysis identifies ALB-EEF1A1 fusion as a novel biomarker in metastatic colorectal cancer
Deeksha Rikhari, Ankit Srivastava, S. Rai, et al.
Cancer Pathogenesis and Therapy (2025)
Open Access
Artificial intelligence for automatic diagnosis and pleomorphic morphological characterization of malignant biliary strictures using digital cholangioscopy
Miguel Mascarenhas, Maria João Almeida, Mariano González-Haba, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
A Nomogram for Predicting the Risk of Liver Metastasis in Non-functional Neuroendocrine Neoplasms: A Population-based Study
Zhipeng Liu, Faji Yang, Yijie Hao, et al.
European Journal of Surgical Oncology (2025) Vol. 51, Iss. 5, pp. 109708-109708
Closed Access
First‐Line Treatment of Icaritin and Thalidomide in a Patient With Hepatocellular Carcinoma With PR: A Case Report
Zhi‐Cheng Jin, Fei Zhou, Zhuo Wang, et al.
Cancer Reports (2025) Vol. 8, Iss. 3
Open Access
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Tricia R. Cottrell, Michael T. Lotze, Alaa M. Ali, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 3, pp. e010928-e010928
Open Access
Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies
Zhihao Lu, Guoping Sun, Jiancheng Li, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 4
Open Access
Liquid biopsy for guiding breast cancer immunotherapy
Emanuela Fina, Elsa Vitale, Simona De Summa, et al.
Immunotherapy (2025), pp. 1-15
Closed Access
Page 1 - Next Page

Scroll to top